Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

March 19, 2021

M Lia Palomba, MD, discusses the data from the TRANSCEND-NHL-001 trial and projected how lisocabtagene maraleucel could fit into the treatment paradigm for patients with MCL.

March 18, 2021

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.

March 05, 2021

Yelena Y. Janjigian, MD, discussed the promise of nivolumab plus chemotherapy in patients with PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma, as well as important biomarkers that should be used to guide sequencing decisions.

March 01, 2021

In our exclusive interview, Paul K. Paik, MD, provides perspective on the FDA approval of tepotinib in MET exon 14-altered metastatic non–small cell lung cancer.

February 26, 2021

The progress made with novel combination regimens coupled with their game-changing data in both frontline and relapsed/refractory chronic lymphocytic leukemia is unprecedented.

February 13, 2021

February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.

February 05, 2021

February 4, 2021 - Despite the threat the coronavirus disease 2019 presents, it’s necessary that patients with cancer continue to receive care at outpatient facilities—a feat that has been made possible at Memorial Sloan Kettering Cancer Center through multidisciplinary efforts, innovative strategy, and technologic advances.

January 29, 2021

January 28, 2021 - Treatment with the KRAS G12C inhibitor sotorasib (formerly AMG 510) elicited a 6.8-month median progression-free survival in patients with KRAS G12C–mutated advanced non–small cell lung cancer.

January 13, 2021

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

January 07, 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

December 28, 2020

December 28, 2020 - The investigational selective estrogen receptor degrader SAR439859 elicited clinical, on-target activity in patients with heavily pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer, even in the presence of multiple resistance mechanisms.

December 02, 2020

Mark G. Kris, MD, discusses the strengths of this year’s New York Lung Cancers Symposium, the advances that have been made over the past year, and potential routes forward in advancing the field of lung cancer.

November 17, 2020

Chung-Han Lee, MD, PhD, discusses the promise of telaglenastat in renal cell carcinoma and the research efforts examining the agent in different combinations.

November 04, 2020

The investigational small molecule, γ-secretase inhibitor AL101 monotherapy was found to elicit deep responses with a significant disease control rate in patients with recurrent or metastatic adenoid cystic carcinoma harboring NOTCH activating mutations.

October 30, 2020

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

October 27, 2020

William D. Tap, MD, discusses the evolution of precision medicine in soft tissue sarcomas.

October 14, 2020

Robert J. Motzer, MD, and Ulka Nitin Vaishampayan, MD, MBBS, FAB, discuss some of the latest updates in metastatic renal cell carcinoma.

October 13, 2020

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

October 09, 2020

Philip W. Kantoff, MD, discusses the evolving treatment landscape of mCRPC, the early efficacy data demonstrated with VERU-111, and other emerging areas of research that are poised to impact the prostate cancer paradigm.

October 08, 2020

Philip W. Kantoff, MD, discusses the need to develop new therapies in metastatic castration-resistant prostate cancer.